US5690954A
(en)
*
|
1987-05-22 |
1997-11-25 |
Danbiosyst Uk Limited |
Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
|
US5571500A
(en)
*
|
1987-06-24 |
1996-11-05 |
Autoimmune, Inc. |
Treatment of autoimmune diseases through administration by inhalation of autoantigens
|
US5849298A
(en)
*
|
1987-06-24 |
1998-12-15 |
Autoimmune Inc. |
Treatment of multiple sclerosis by oral administration of bovine myelin
|
US5641474A
(en)
*
|
1987-06-24 |
1997-06-24 |
Autoimmune, Inc. |
Prevention of autoimmune diseases by aerosol administration of autoantigens
|
US5571499A
(en)
*
|
1987-06-24 |
1996-11-05 |
Autoimmune, Inc. |
Treatment of autoimmune diseases by aerosol administration of autoantigens
|
US5645820A
(en)
*
|
1987-06-24 |
1997-07-08 |
Autoimmune, Inc. |
Treatment of autoimmune diseases by aerosol administration of autoantigens
|
EP0308181A1
(en)
*
|
1987-09-14 |
1989-03-22 |
Novo Nordisk A/S |
Trans-mucosal delivery formulations and a method for preparation thereof
|
GB8723846D0
(en)
*
|
1987-10-10 |
1987-11-11 |
Danbiosyst Ltd |
Bioadhesive microsphere drug delivery system
|
ES2061688T3
(es)
*
|
1987-11-13 |
1994-12-16 |
Smithkline Beecham Farma |
Composiciones farmaceuticas que comprenden una calcitonina y un glicirricinato como mejorador de la absorcion.
|
GB8822857D0
(en)
*
|
1988-09-29 |
1988-11-02 |
Patralan Ltd |
Pharmaceutical formulations
|
EP0458894B1
(en)
*
|
1989-02-17 |
1996-05-15 |
The Liposome Company, Inc. |
Lipid excipient for nasal delivery and topical application
|
IT8920486A0
(it)
*
|
1989-05-12 |
1989-05-12 |
Isf Spa |
Composizioni farmaceutiche.
|
GB8918879D0
(en)
*
|
1989-08-18 |
1989-09-27 |
Danbiosyst Uk |
Pharmaceutical compositions
|
US5725871A
(en)
*
|
1989-08-18 |
1998-03-10 |
Danbiosyst Uk Limited |
Drug delivery compositions comprising lysophosphoglycerolipid
|
GB9007052D0
(en)
*
|
1990-03-29 |
1990-05-30 |
Skua Investments Ltd |
Pharmaceutical formulations
|
GB9012663D0
(en)
*
|
1990-06-07 |
1990-08-01 |
Erba Carlo Spa |
Galenic formulations containing cyclodextrins
|
IL99699A
(en)
*
|
1990-10-10 |
2002-04-21 |
Autoimmune Inc |
Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
|
IT1250691B
(it)
|
1991-07-22 |
1995-04-21 |
Giancarlo Santus |
Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
|
DK36492D0
(da)
*
|
1992-03-19 |
1992-03-19 |
Novo Nordisk As |
Praeparat
|
US5482706A
(en)
*
|
1992-04-17 |
1996-01-09 |
Takeda Chemical Industries, Ltd. |
Transmucosal therapeutic composition
|
DE4214953C2
(de)
*
|
1992-05-06 |
1995-05-18 |
Arrowdean Ltd |
Arzneimittel zur Erhöhung des Testosteronspiegels
|
DE4218291A1
(de)
*
|
1992-06-03 |
1993-12-09 |
Mattern Et Partner Pharmazeuti |
Dosierspray für pernasale Applikation
|
SI9300468A
(en)
*
|
1992-10-14 |
1994-06-30 |
Hoffmann La Roche |
Injectable composition for the sustained release of biologically active compounds
|
US5830853A
(en)
|
1994-06-23 |
1998-11-03 |
Astra Aktiebolag |
Systemic administration of a therapeutic preparation
|
US5747445A
(en)
*
|
1993-06-24 |
1998-05-05 |
Astra Aktiebolag |
Therapeutic preparation for inhalation
|
US5506203C1
(en)
*
|
1993-06-24 |
2001-02-06 |
Astra Ab |
Systemic administration of a therapeutic preparation
|
TW402506B
(en)
*
|
1993-06-24 |
2000-08-21 |
Astra Ab |
Therapeutic preparation for inhalation
|
IS1796B
(is)
*
|
1993-06-24 |
2001-12-31 |
Ab Astra |
Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
|
US6794357B1
(en)
|
1993-06-24 |
2004-09-21 |
Astrazeneca Ab |
Compositions for inhalation
|
US6632456B1
(en)
|
1993-06-24 |
2003-10-14 |
Astrazeneca Ab |
Compositions for inhalation
|
DK0748213T3
(da)
|
1994-03-07 |
2004-08-02 |
Nektar Therapeutics |
Fremgangsmåder og sammensætninger til pulmonal indgivelse af insulin
|
US6165976A
(en)
|
1994-06-23 |
2000-12-26 |
Astra Aktiebolag |
Therapeutic preparation for inhalation
|
ATE223202T1
(de)
*
|
1994-09-30 |
2002-09-15 |
Mika Pharma Ges Fuer Die Entwi |
Pharmazeutische zusammensetzung
|
US6524557B1
(en)
|
1994-12-22 |
2003-02-25 |
Astrazeneca Ab |
Aerosol formulations of peptides and proteins
|
SE9404468D0
(sv)
*
|
1994-12-22 |
1994-12-22 |
Astra Ab |
Powder formulations
|
US5869602A
(en)
|
1995-03-17 |
1999-02-09 |
Novo Nordisk A/S |
Peptide derivatives
|
US5780014A
(en)
*
|
1995-04-14 |
1998-07-14 |
Inhale Therapeutic Systems |
Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
|
US5653987A
(en)
*
|
1995-05-16 |
1997-08-05 |
Modi; Pankaj |
Liquid formulations for proteinic pharmaceuticals
|
US5856446A
(en)
*
|
1995-07-07 |
1999-01-05 |
Autoimmune Inc. |
Method of treating rheumatoid arthritis with low dose type II collagen
|
JPH11292787A
(ja)
*
|
1995-08-15 |
1999-10-26 |
Asahi Chem Ind Co Ltd |
生理活性ペプチドを含有する経粘膜投与製剤
|
US5874064A
(en)
|
1996-05-24 |
1999-02-23 |
Massachusetts Institute Of Technology |
Aerodynamically light particles for pulmonary drug delivery
|
US6652837B1
(en)
|
1996-05-24 |
2003-11-25 |
Massachusetts Institute Of Technology |
Preparation of novel particles for inhalation
|
US5985309A
(en)
*
|
1996-05-24 |
1999-11-16 |
Massachusetts Institute Of Technology |
Preparation of particles for inhalation
|
DE122009000079I2
(de)
|
1996-08-30 |
2011-06-16 |
Novo Nordisk As Novo Alle |
Glp-1 derivate
|
US6017545A
(en)
*
|
1998-02-10 |
2000-01-25 |
Modi; Pankaj |
Mixed micellar delivery system and method of preparation
|
EP1840134B1
(en)
|
1998-02-27 |
2016-04-13 |
Novo Nordisk A/S |
GLP-1 derivatives
|
EP1062240B1
(en)
|
1998-02-27 |
2010-04-28 |
Novo Nordisk A/S |
N-terminally modified glp-1 derivatives
|
JP2002512175A
(ja)
|
1998-02-27 |
2002-04-23 |
ノボ ノルディスク アクティーゼルスカブ |
Glp−1類似体の誘導体類
|
TWI243687B
(en)
|
1998-04-21 |
2005-11-21 |
Teijin Ltd |
Pharmaceutical composition for application to mucosa
|
EP1306091A3
(en)
|
1998-07-31 |
2003-05-21 |
Novo Nordisk A/S |
Stimulation of beta cell proliferation
|
US6290987B1
(en)
|
1998-09-27 |
2001-09-18 |
Generex Pharmaceuticals, Inc. |
Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
|
US6849263B2
(en)
|
1998-12-21 |
2005-02-01 |
Generex Pharmaceutical Incorporated |
Pharmaceutical compositions for buccal delivery of pain relief medications
|
US6271200B1
(en)
|
1998-12-21 |
2001-08-07 |
Generex Pharmaceuticals Inc. |
Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
|
US6436367B1
(en)
|
1998-12-21 |
2002-08-20 |
Generex Pharmaceuticals Inc. |
Aerosol formulations for buccal and pulmonary application
|
US7087215B2
(en)
|
1998-12-21 |
2006-08-08 |
Generex Pharmaceuticals Incorporated |
Methods of administering and enhancing absorption of pharmaceutical agents
|
US6540982B1
(en)
*
|
2000-01-25 |
2003-04-01 |
Aeropharm Technology Incorporated |
Medical aerosol formulation
|
JP2003525908A
(ja)
|
2000-03-08 |
2003-09-02 |
ノボ ノルディスク アクティーゼルスカブ |
血清脂質の低下
|
GB0027357D0
(en)
|
2000-11-09 |
2000-12-27 |
Bradford Particle Design Plc |
Particle formation methods and their products
|
US20040176476A1
(en)
*
|
2001-06-22 |
2004-09-09 |
Gyurik Robert J. |
Pharmaceutical composition
|
US7244703B2
(en)
|
2001-06-22 |
2007-07-17 |
Bentley Pharmaceuticals, Inc. |
Pharmaceutical compositions and methods for peptide treatment
|
GB0205327D0
(en)
*
|
2002-03-06 |
2002-04-17 |
Glaxo Group Ltd |
compounds
|
US9339459B2
(en)
|
2003-04-24 |
2016-05-17 |
Nektar Therapeutics |
Particulate materials
|
PL2107069T3
(pl)
|
2003-08-05 |
2013-06-28 |
Novo Nordisk As |
Nowe pochodne insuliny
|
PL2275439T3
(pl)
|
2003-08-05 |
2014-09-30 |
Novo Nordisk As |
Nowe pochodne insuliny
|
BRPI0414539B8
(pt)
|
2003-09-19 |
2021-05-25 |
Novo Nordisk As |
composto, composição farmacêutica, e, uso de um composto
|
WO2005092301A1
(en)
|
2004-03-26 |
2005-10-06 |
Universita' Degli Studi Di Parma |
Insulin highly respirable microparticles
|
CN1299770C
(zh)
*
|
2004-05-31 |
2007-02-14 |
刘近周 |
多功能鼻腔和鼻窦洁疗液
|
CN101128487B
(zh)
|
2004-12-02 |
2012-10-10 |
杜门蒂斯有限公司 |
靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体
|
JP4933455B2
(ja)
|
2005-02-02 |
2012-05-16 |
ノヴォ ノルディスク アー/エス |
新規のインスリン誘導体
|
ES2490243T3
(es)
|
2005-02-02 |
2014-09-03 |
Novo Nordisk A/S |
Derivados de insulina
|
US8722620B2
(en)
|
2006-02-27 |
2014-05-13 |
Novo Nordisk A/S |
Insulin derivatives
|
US8796205B2
(en)
|
2006-05-09 |
2014-08-05 |
Novo Nordisk A/S |
Insulin derivative
|
RU2451029C2
(ru)
|
2006-05-09 |
2012-05-20 |
Ново Нордиск А/С |
Производное инсулина
|
JP5688969B2
(ja)
|
2007-07-16 |
2015-03-25 |
ノボ・ノルデイスク・エー/エス |
プロテアーゼに対して安定しているペグ化インスリンアナログ
|
ES2526924T3
(es)
|
2007-08-15 |
2015-01-16 |
Novo Nordisk A/S |
Insulinas con una fracción acilo que comprende unidades repetitivas de aminoácidos que contienen alquilenglicol
|
EP2178912B1
(en)
|
2007-08-15 |
2015-07-08 |
Novo Nordisk A/S |
Insulin analogues with an acyl and aklylene glycol moiety
|
WO2009115469A1
(en)
|
2008-03-18 |
2009-09-24 |
Novo Nordisk A/S |
Protease stabilized, acylated insulin analogues
|
CA2718480A1
(en)
|
2008-03-31 |
2009-10-08 |
Glaxo Group Limited |
Drug fusions and conjugates
|
WO2009121884A1
(en)
|
2008-04-01 |
2009-10-08 |
Novo Nordisk A/S |
Insulin albumin conjugates
|
US8277781B2
(en)
|
2009-03-13 |
2012-10-02 |
Luitpold Pharmaceuticals, Inc. |
Device for intranasal administration
|
US8551454B2
(en)
|
2009-03-13 |
2013-10-08 |
Luitpold Pharmaceuticals, Inc. |
Device for intranasal administration
|
EP2411054A2
(en)
|
2009-03-27 |
2012-02-01 |
Glaxo Group Limited |
Drug fusions and conjugates
|
MX2012003939A
(es)
|
2009-09-30 |
2012-07-30 |
Glaxo Group Ltd |
Fusiones y conjugados de farmaco.
|
US20130261051A1
(en)
|
2010-10-27 |
2013-10-03 |
Thue Johansen |
Treating Diabetes Melitus Using Insulin Injections Administered With Varying Injection Intervals
|
US9808030B2
(en)
|
2011-02-11 |
2017-11-07 |
Grain Processing Corporation |
Salt composition
|
WO2012136792A2
(en)
|
2011-04-07 |
2012-10-11 |
Glaxo Group Limited |
Cck compositions
|
WO2012136790A1
(en)
|
2011-04-07 |
2012-10-11 |
Glaxo Group Limited |
Compositions comprising fusion proteins or conjugates with an improved half -life
|
EP2788027A2
(en)
|
2011-12-09 |
2014-10-15 |
Novo Nordisk A/S |
Glp-1 agonists
|
WO2013164375A1
(en)
|
2012-05-01 |
2013-11-07 |
Novo Nordisk A/S |
Pharmaceutical composition
|
WO2014093688A1
(en)
|
2012-12-12 |
2014-06-19 |
1Massachusetts Institute Of Technology |
Compositions and methods for functional nucleic acid delivery
|
WO2014093696A2
(en)
|
2012-12-12 |
2014-06-19 |
Massachusetts Institute Of Technology |
Insulin derivatives for diabetes treatment
|
CA2932477C
(en)
|
2013-12-06 |
2023-10-10 |
Baikang (Suzhou) Co., Ltd |
Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
|
EP3258919B2
(en)
*
|
2015-02-17 |
2022-11-09 |
Eli Lilly and Company |
Nasal powder formulation for treatment of hypoglycemia
|
EP3873434A1
(en)
|
2018-11-04 |
2021-09-08 |
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. |
Nasal compositions and methods
|